Conditions: Obesity & Overweight; Weight Loss; Preventative Health; Body Weight; Cardiovascular Disease Risk Factor
Interventions: Behavioral: Noom Weight; Behavioral: Free Tier; Behavioral: Education-only control; Drug: Semaglutide; Drug: Tirzepatide; Drug: Microdose semaglutide; Drug: Microdose tirzepatide
Sponsors: Noom Inc.
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
